Oversulfated heparins with low anticoagulant activity are strong and fast inhibitors of hepcidin expression in vitro and in vivo

Biochemical Pharmacology

Volumn 92, Issue 3, 2014, Pages 467-475

  Poli, Maura ^a   Asperti, Michela ^a   Ruzzenenti, Paola ^a   Mandelli, Luca ^b   Campostrini, Natascia ^c   Martini, Giuliana ^d   Di Somma, Margherita ^a   Maccarinelli, Federica ^a   Girelli, Domenico ^c   Naggi, Annamaria ^b   Arosio, Paolo ^a  

^a UNIVERSITY OF BRESCIA   (Italy)

^b Istituto di Ricerche Chimiche e Biochimiche G Ronzoni   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d Azienda Ospedaliero Universitaria di Parma   (Italy)

Author keywords

Anemia of chronic diseases; Hepcidin; Iron absorption and metabolism; Low molecular weight heparins

Indexed keywords

BLOOD CLOTTING FACTOR 10A; BLOOD CLOTTING FACTOR 10A INHIBITOR; GLYCOL; HEPARIN; HEPARIN DERIVATIVE; HEPCIDIN; IRON; LOW MOLECULAR WEIGHT HEPARIN; MANGANESE; MESSENGER RNA; OVERSULFATED LOW MOLECULAR WEIGHT HEPARIN 19; PALLADIUM; RO 82; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; ANTICOAGULANT AGENT; FACTOR IIA; PROTHROMBIN; SULFATE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTICOAGULATION; ARTICLE; CONTROLLED STUDY; HEPG2 CELL LINE; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; IRON ABSORPTION; IRON BLOOD LEVEL; IRON METABOLISM; LONG TERM CARE; MOLECULAR WEIGHT; MOUSE; NONHUMAN; OXIDATION REDUCTION REACTION; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; SPLEEN; SULFATION; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CHEMISTRY; DRUG EFFECTS; LIVER; METABOLISM; STRUCTURE ACTIVITY RELATION;

ANIMALS; ANTICOAGULANTS; FACTOR XA; FACTOR XA INHIBITORS; HEP G2 CELLS; HEPARIN; HEPARIN, LOW-MOLECULAR-WEIGHT; HEPCIDINS; HUMANS; LIVER; MICE, INBRED C57BL; PROTHROMBIN; STRUCTURE-ACTIVITY RELATIONSHIP; SULFATES; TRIGLYCERIDES;

EID: 84910652964     PISSN: 00062952     EISSN: 18732968     Source Type: Journal    
DOI: 10.1016/j.bcp.2014.09.007     Document Type: Article

References (39)

1. Hentze MW, Muckenthaler MU, Galy B, Camaschella C. Two to tango: regulation of Mammalian iron metabolism. Cell 2010;142:24-38.
2. Harrison P, Arosio P. Ferritins: Molecular properties, iron storage function and cellular regulation. Biochim Biophys Acta Bioenergetics 1996;1275:161-203.
3. Ganz T, Nemeth E. Hepcidin and disorders of iron metabolism. Annu Rev Med 2011;62:347-60.
4. Nemeth E, Ganz T. Regulation of iron metabolism by hepcidin. Annu Rev Nutr 2006;26:323-42.
5. Nemeth E, Tuttle MS, Powelson J, Vaughn MB, Donovan A, Ward DM, et al. Hepcidin regulates cellular iron efflux by binding to ferroportin and inducing its internalization. Science 2004;306:2090-3.
6. Wessling-Resnick M. Iron homeostasis and the inflammatory response. Annu Rev Nutr. 2010;30:105-22.
7. Babitt J, Huang F, Wrighting D, Xia Y, Sidis Y, Samad T, et al. Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression. Nat Genet 2006;38:531-9.
8. Silvestri L, Pagani A, Nai A, De Domenico I, Kaplan J, Camaschella C. The serine protease matriptase-2 (TMPRSS6) inhibits hepcidin activation by cleaving membrane hemojuvelin. Cell Metab 2008;8:502-11.
9. Verga Falzacappa MV, Vujic Spasic M, Kessler R, Stolte J, Hentze MW, Muckenthaler MU. STAT3 mediates hepatic hepcidin expression and its inflammatory stimulation. Blood 2007;109:353-8.
10. Kim A, Fung E, Parikh SG, Valore EV, Gabayan V, Nemeth E, et al. A mouse model of anemia of inflammation: complex pathogenesis with partial dependence on hepcidin. Blood 2014;123:1129-36.
11. Fung E, Nemeth E. Manipulation of the hepcidin pathway for therapeutic purposes. Haematologica 2013;98:1667-76.
12. Ganz T, Nemeth E. The hepcidin-ferroportin system as a therapeutic target in anemias and iron overload disorders. Hematol Am Soc Hematol Educ Program 2011;2011:538-42.
13. Poli M, Asperti M, Ruzzenenti P, Regoni M, Arosio P. Hepcidin antagonists for potential treatments of disorders with hepcidin excess. Front Pharmacol 2014;5:86.
14. Poli M, Girelli D, Campostrini N, Maccarinelli F, Finazzi D, Luscieti S, et al. Heparin: a potent inhibitor of hepcidin expression in vitro and in vivo. Blood 2011;117:997-1004.
15. Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, et al. Glycol-split non-anticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 2014.
16. Benito Casu, Annamaria Naggi, Torri G. Re-visiting the structure of heparin. Carbohyd Res 2014.
17. Lindahl U, Bäckström G, Thunberg L, Leder IG. Evidence for a 3-O-sulfated D-glucosamine residue in the antithrombin-binding sequence of heparin. Proc Natl Acad Sci USA 1980;77:6551-5.
18. Naggi A. Glycol-splitting as a device for modulating inhibition of growth factors and heparanase by heparin and heparin derivatives. In: Garg HG, LRJaHCA, editors. Chemistry and Biology of Heparin and Heparan Sulfate. Elsevier; 2005. p. 461-82.
19. Toida T, Maruyama T, Ogita Y, Suzuki A, Toyoda H, Imanari T, et al. Preparation and anticoagulant activity of fully O-sulphonated glycosaminoglycans. Int J Biol Macromol 1999;26:233-41.
20. Naggi A, Torri G, Casu B, Pangrazzi J, Abbadini M, Zametta M, et al. Super-sulfated heparin fragments, a new type of low-molecular weight heparin. Physico-chemical and pharmacological properties. Biochem Pharmacol 1987;36:1895-900.
21. Sissi C, Lucatello L, Naggi A, Torri G, Palumbo M. Interactions of low-molecular-weight semi-synthetic sulfated heparins with human leukocyte elastase and human Cathepsin G. Biochem Pharmacol 2006;71:287-93.
22. Yates EA, Santini F, De Cristofano B, Payre N, Cosentino C, Guerrini M, et al. Effect of substitution pattern on 1H, 13C NMR chemical shifts and 1J(CH) coupling constants in heparin derivatives. Carbohydr Res 2000;329:239-47.
23. Guerrini M, Naggi A, Guglieri S, Santarsiero R, Torri G. Complex glycosaminoglycans: profiling substitution patterns by two-dimensional nuclear magnetic resonance spectroscopy. Anal Biochem 2005;337:35-47.
24. Guerrini M, Guglieri S, Naggi A, Sasisekharan R, Torri G. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy. Semin Thromb Hemost 2007;33:478-87.
25. Castagna A, Campostrini N, Zaninotto F, Girelli D. Hepcidin assay in serum by SELDI-TOF-MS and other approaches. J Proteomics 2010;73:527-36.
26. Tjalsma H, Laarakkers CM, van Swelm RP, Theurl M, Theurl I, Kemna EH, et al. Mass spectrometry analysis of hepcidin peptides in experimental mouse models. PLoS One 2011;6:e16762.
27. Roetto A, Di Cunto F, Pellegrino R, Hirsch E, Azzolino O, Bondi A, et al. Comparison of 3 Tfr2-deficient murine models suggests distinct functions for Tfr2-alpha and Tfr2-beta isoforms in different tissues. Blood 2010;115:3382-9.
28. Poli M, Asperti M, Naggi A, Campostrini N, Girelli D, Corbella M, et al. Glycol-split nonanticoagulant heparins are inhibitors of hepcidin expression in vitro and in vivo. Blood 2014;123:1564-73.
29. Srinivasan SR, Vijayagopal P, Dalferes ER, Abbate B, Radhakrishnamurthy B, Berenson GS. Low density lipoprotein retention by aortic tissue: contribution of extracellular matrix. Atherosclerosis 1986;62:201-8.
30. Cardin AD, Jackson RL, Elledge B, Feldhake D. Dependence on heparin chain-length of the interaction of heparin with human plasma low density lipoproteins. Int J Biol Macromol 1989;11:59-62.
31. Guo W, Bachman E, Li M, Roy CN, Blusztajn J, Wong S, et al. Testosterone administration inhibits hepcidin transcription and is associated with increased iron incorporation into red blood cells. Aging Cell 2013;12:280-91.
32. Weitz JI. Low-molecular-weight heparins. N Engl J Med 1997;337:688-98.
33. Schauer UJ, Schauer I, Rühling K, Thielmann K. Stimulation of lecithin: cholesterol acyl transfer by intravenous injection of heparin. Biomed Biochim Acta 1984;43:1165-72.
34. Rubinstein A, Gibson JC, Paterniti JR, Kakis G, Little A, Ginsberg HN, et al. Effect of heparin-induced lipolysis on the distribution of apolipoprotein among lipoprotein subclasses. Studies with patients deficient in hepatic triglyceride lipase and lipoprotein lipase. J Clin Invest 1985;75:710-21.
35. Aviram M, Rosenblat M, Potesman M, Dankner G, Brook JG. Plasma lipoprotein and platelet function after heparin injection: studies in normal fasted and postprandial and in type V hyperlipoproteinemic subjects. Biochem Med Metab Biol 1986;35:279-92.
36. Casu B, Diamantini G, Fedeli G, Mantovani M, Oreste P, Pescador R, et al. Retention of antilipemic activity by periodate-oxidized non-anticoagulant heparins. Arzneimittelforschung 1986;36:637-42.
37. Casu B, Naggi A, Torri G. Heparin-derived heparan sulfate mimics to modulate heparan sulfate-protein interaction in inflammation and cancer. Matrix Biol 2010;29:442-52.
38. Mummery RS, Rider CC. Characterization of the heparin-binding properties of IL-6. J Immunol 2000;165:5671-9.
39. Glusa E, Barthel W, Schenk J, Radziwon P, Butti A, Markwardt F, et al. Effects of a supersulfated low molecular weight heparin (IK-SSH) on different hemostatic parameters. Haemostasis 1998;28:45-56.